| Overview |
| bsm-61534r-100ul |
| PDCD4 Recombinant Antibody |
| WB, FCM, IHC-P, IHC-F, IF(IHC-P), IF(ICC) |
| Human, Mouse |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human PDCD4 |
| Recombinant |
| IgG |
| Lot dependent |
| Purified by Protein A. |
| 0.01M TBS (pH 7.4), 1% BSA, 0.02% Proclin 300, and 50% Glycerol |
| Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 27250 |
| Q53EL6 |
| Cytoplasm, Nucleus |
| Death up-regulated gene protein; Dug; H731; Ma3; Neoplastic transformation inhibitor; Nuclear antigen H731; Pdcd4; Programmed cell death protein 4; Tis. |
| Inhibits translation initiation and cap-dependent translation. May excert its function by hindering the interaction between EIF4A1 and EIF4G. Inhibits the helicase activity of EIF4A. Modulates the activation of JUN kinase. Down-regulates the expression of MAP4K1, thus inhibiting events important in driving invasion, namely, MAPK85 activation and consequent JUN-dependent transcription. |
| Application Dilution |
| WB |
1:500-2000 |
| FCM |
FCM1:50-100 |
| IHC-P |
IHC-P1:100-500 |
| IHC-F |
IHC-F1:100-500 |
| IF(IHC-P) |
IFIHC-P1:100-500 |
| IF(ICC) |
IFICC1:50-200 |